Sage Capital Advisors llc Purchases 617 Shares of MEDNAX Inc (NYSE:MD)

Sage Capital Advisors llc grew its position in MEDNAX Inc (NYSE:MD) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,435 shares of the company’s stock after purchasing an additional 617 shares during the period. Sage Capital Advisors llc owned about 0.07% of MEDNAX worth $1,568,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Wedge Capital Management L L P NC boosted its holdings in MEDNAX by 3.8% in the fourth quarter. Wedge Capital Management L L P NC now owns 18,693 shares of the company’s stock worth $519,000 after purchasing an additional 677 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in MEDNAX during the fourth quarter worth approximately $166,000. Altfest L J & Co. Inc. increased its holdings in MEDNAX by 5.6% in the fourth quarter. Altfest L J & Co. Inc. now owns 9,581 shares of the company’s stock worth $266,000 after purchasing an additional 510 shares in the last quarter. Millennium Management LLC increased its holdings in MEDNAX by 381.5% in the third quarter. Millennium Management LLC now owns 340,081 shares of the company’s stock worth $7,692,000 after purchasing an additional 269,457 shares in the last quarter. Finally, Man Group plc lifted its stake in MEDNAX by 97.9% in the third quarter. Man Group plc now owns 431,790 shares of the company’s stock valued at $9,767,000 after buying an additional 213,629 shares during the period. Institutional investors own 92.30% of the company’s stock.

In related news, Director Md Pascal J. Goldschmidt sold 5,000 shares of MEDNAX stock in a transaction on Friday, November 1st. The stock was sold at an average price of $22.88, for a total value of $114,400.00. Following the completion of the sale, the director now owns 10,821 shares of the company’s stock, valued at $247,584.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.40% of the company’s stock.

Shares of MEDNAX stock traded up $0.29 on Thursday, hitting $27.58. 12,102 shares of the company traded hands, compared to its average volume of 830,544. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 1.35. The company has a market cap of $2.33 billion, a PE ratio of 7.87, a PEG ratio of 1.03 and a beta of 0.78. The stock’s 50 day moving average price is $26.96 and its 200-day moving average price is $24.21. MEDNAX Inc has a 52 week low of $19.93 and a 52 week high of $38.88.

MEDNAX (NYSE:MD) last issued its earnings results on Friday, November 1st. The company reported $0.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.83 by $0.08. The business had revenue of $888.70 million during the quarter, compared to analyst estimates of $876.20 million. MEDNAX had a positive return on equity of 10.38% and a negative net margin of 40.86%. MEDNAX’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the company posted $0.94 EPS. As a group, research analysts anticipate that MEDNAX Inc will post 3.03 EPS for the current fiscal year.

A number of equities analysts have issued reports on the company. Citigroup downgraded MEDNAX from a “buy” rating to a “neutral” rating and set a $29.00 price target for the company. in a research note on Friday, January 3rd. TheStreet downgraded shares of MEDNAX from a “c-” rating to a “d” rating in a research report on Friday, November 1st. UBS Group cut their target price on shares of MEDNAX from $19.00 to $18.00 and set a “sell” rating for the company in a research report on Friday, October 18th. JPMorgan Chase & Co. increased their price target on MEDNAX from $26.00 to $33.00 and gave the company a “neutral” rating in a report on Friday, December 20th. Finally, Mizuho set a $25.00 target price on MEDNAX and gave the company a “hold” rating in a report on Friday, November 1st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $27.33.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Story: What is the Current Ratio?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.